Enfusion Cost Of Revenue vs Other Operating Expenses Analysis

ENFN Stock

USD 10.76 0.04 0.37%

Enfusion financial indicator trend analysis is much more than just examining Enfusion latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Enfusion is a good investment. Please check the relationship between Enfusion Cost Of Revenue and its Other Operating Expenses accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enfusion. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.

To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.

Cost Of Revenue vs Other Operating Expenses

Cost Of Revenue vs Other Operating Expenses Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Enfusion Cost Of Revenue account and Other Operating Expenses. At this time, the significance of the direction appears to have strong relationship.

The correlation between Enfusion's Cost Of Revenue and Other Operating Expenses is 0.64. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Other Operating Expenses in the same time period over historical financial statements of Enfusion, assuming nothing else is changed. The correlation between historical values of Enfusion's Cost Of Revenue and Other Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Enfusion are associated (or correlated) with its Other Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Operating Expenses has no effect on the direction of Cost Of Revenue i.e., Enfusion's Cost Of Revenue and Other Operating Expenses go up and down completely randomly.

Correlation Coefficient

0.64

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Cost Of Revenue

Cost of Revenue is found on Enfusion income statement and represents the costs associated with goods and services Enfusion provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Enfusion. It is also known as Enfusion overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most indicators from Enfusion's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Enfusion current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enfusion. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.

To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.At this time, Enfusion's Tax Provision is very stable compared to the past year. As of the 18th of April 2025, Sales General And Administrative To Revenue is likely to grow to 0.61, while Selling General Administrative is likely to drop about 76.1 M.

	2022	2023	2024	2025 (projected)
Interest Expense	413K	1.6M	1.9M	2.0M
Depreciation And Amortization	6.6M	10.0M	11.5M	12.1M

Interest Expense Depreciation And Amortization

Enfusion fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital
Total Assets		-0.36	0.69	0.87	0.91	-0.56	0.91	0.92	-0.97	-0.82	-0.87	0.8	0.96	0.92	0.85	0.21	0.9	0.96	0.98	-0.18	-0.83	0.86	0.88	0.95	-0.79	0.96
Short Long Term Debt Total	-0.36		-0.19	-0.19	-0.67	-0.44	-0.67	-0.29	0.46	0.79	0.48	-0.44	-0.39	-0.29	-0.24	-0.21	0.03	-0.39	-0.31	0.27	0.79	-0.3	-0.38	-0.57	0.84	-0.55
Other Current Liab	0.69	-0.19		0.93	0.6	-0.43	0.6	0.88	-0.6	-0.4	-0.74	0.21	0.48	0.89	0.82	-0.44	0.55	0.48	0.79	0.51	-0.51	0.78	0.32	0.6	-0.45	0.61
Total Current Liabilities	0.87	-0.19	0.93		0.73	-0.57	0.74	0.98	-0.79	-0.54	-0.89	0.47	0.7	0.98	0.88	-0.18	0.77	0.7	0.94	0.31	-0.63	0.93	0.53	0.77	-0.57	0.78
Total Stockholder Equity	0.91	-0.67	0.6	0.73		-0.34	1.0	0.82	-0.96	-0.95	-0.89	0.82	0.89	0.82	0.83	0.16	0.65	0.89	0.87	-0.21	-0.98	0.83	0.83	0.99	-0.95	0.99
Other Liab	-0.56	-0.44	-0.43	-0.57	-0.34		-0.34	-0.54	0.54	0.15	0.43	-0.34	-0.52	-0.54	-0.71	0.13	-0.69	-0.52	-0.57	-0.09	0.17	-0.6	-0.48	-0.44	0.04	-0.46
Net Tangible Assets	0.91	-0.67	0.6	0.74	1.0	-0.34		0.83	-0.96	-0.95	-0.89	0.82	0.88	0.83	0.83	0.15	0.65	0.88	0.88	-0.2	-0.98	0.84	0.83	0.99	-0.95	0.99
Property Plant And Equipment Net	0.92	-0.29	0.88	0.98	0.82	-0.54	0.83		-0.88	-0.65	-0.91	0.62	0.77	1.0	0.89	-0.12	0.81	0.77	0.98	0.2	-0.74	0.92	0.65	0.85	-0.68	0.86
Current Deferred Revenue	-0.97	0.46	-0.6	-0.79	-0.96	0.54	-0.96	-0.88		0.88	0.88	-0.87	-0.95	-0.87	-0.86	-0.19	-0.82	-0.95	-0.94	0.22	0.91	-0.86	-0.9	-0.99	0.86	-0.99
Net Debt	-0.82	0.79	-0.4	-0.54	-0.95	0.15	-0.95	-0.65	0.88		0.75	-0.81	-0.87	-0.65	-0.64	-0.37	-0.54	-0.87	-0.73	0.44	0.98	-0.65	-0.85	-0.93	0.98	-0.92
Retained Earnings	-0.87	0.48	-0.74	-0.89	-0.89	0.43	-0.89	-0.91	0.88	0.75		-0.63	-0.75	-0.9	-0.87	0.01	-0.64	-0.75	-0.92	-0.13	0.84	-0.98	-0.61	-0.89	0.77	-0.9
Accounts Payable	0.8	-0.44	0.21	0.47	0.82	-0.34	0.82	0.62	-0.87	-0.81	-0.63		0.85	0.61	0.56	0.37	0.73	0.85	0.72	-0.48	-0.8	0.57	0.92	0.86	-0.8	0.84
Cash	0.96	-0.39	0.48	0.7	0.89	-0.52	0.88	0.77	-0.95	-0.87	-0.75	0.85		0.78	0.74	0.43	0.87	1.0	0.87	-0.45	-0.83	0.73	0.96	0.93	-0.8	0.93
Non Current Assets Total	0.92	-0.29	0.89	0.98	0.82	-0.54	0.83	1.0	-0.87	-0.65	-0.9	0.61	0.78		0.9	-0.13	0.81	0.78	0.98	0.2	-0.74	0.92	0.66	0.85	-0.68	0.86
Non Currrent Assets Other	0.85	-0.24	0.82	0.88	0.83	-0.71	0.83	0.89	-0.86	-0.64	-0.87	0.56	0.74	0.9		-0.24	0.69	0.74	0.89	0.19	-0.72	0.93	0.64	0.85	-0.62	0.86
Other Assets	0.21	-0.21	-0.44	-0.18	0.16	0.13	0.15	-0.12	-0.19	-0.37	0.01	0.37	0.43	-0.13	-0.24		0.25	0.43	0.05	-0.89	-0.2	-0.1	0.45	0.19	-0.27	0.17
Long Term Debt	0.9	0.03	0.55	0.77	0.65	-0.69	0.65	0.81	-0.82	-0.54	-0.64	0.73	0.87	0.81	0.69	0.25		0.87	0.87	-0.2	-0.53	0.69	0.82	0.74	-0.5	0.75
Cash And Short Term Investments	0.96	-0.39	0.48	0.7	0.89	-0.52	0.88	0.77	-0.95	-0.87	-0.75	0.85	1.0	0.78	0.74	0.43	0.87		0.87	-0.45	-0.83	0.73	0.96	0.93	-0.8	0.93
Net Receivables	0.98	-0.31	0.79	0.94	0.87	-0.57	0.88	0.98	-0.94	-0.73	-0.92	0.72	0.87	0.98	0.89	0.05	0.87	0.87		0.02	-0.79	0.93	0.77	0.91	-0.74	0.92
Common Stock Shares Outstanding	-0.18	0.27	0.51	0.31	-0.21	-0.09	-0.2	0.2	0.22	0.44	-0.13	-0.48	-0.45	0.2	0.19	-0.89	-0.2	-0.45	0.02		0.26	0.2	-0.57	-0.23	0.33	-0.21
Non Current Liabilities Total	-0.83	0.79	-0.51	-0.63	-0.98	0.17	-0.98	-0.74	0.91	0.98	0.84	-0.8	-0.83	-0.74	-0.72	-0.2	-0.53	-0.83	-0.79	0.26		-0.74	-0.79	-0.95	0.99	-0.95
Inventory	0.86	-0.3	0.78	0.93	0.83	-0.6	0.84	0.92	-0.86	-0.65	-0.98	0.57	0.73	0.92	0.93	-0.1	0.69	0.73	0.93	0.2	-0.74		0.58	0.85	-0.66	0.86
Other Current Assets	0.88	-0.38	0.32	0.53	0.83	-0.48	0.83	0.65	-0.9	-0.85	-0.61	0.92	0.96	0.66	0.64	0.45	0.82	0.96	0.77	-0.57	-0.79	0.58		0.88	-0.78	0.88
Other Stockholder Equity	0.95	-0.57	0.6	0.77	0.99	-0.44	0.99	0.85	-0.99	-0.93	-0.89	0.86	0.93	0.85	0.85	0.19	0.74	0.93	0.91	-0.23	-0.95	0.85	0.88		-0.92	1.0
Total Liab	-0.79	0.84	-0.45	-0.57	-0.95	0.04	-0.95	-0.68	0.86	0.98	0.77	-0.8	-0.8	-0.68	-0.62	-0.27	-0.5	-0.8	-0.74	0.33	0.99	-0.66	-0.78	-0.92		-0.9
Net Invested Capital	0.96	-0.55	0.61	0.78	0.99	-0.46	0.99	0.86	-0.99	-0.92	-0.9	0.84	0.93	0.86	0.86	0.17	0.75	0.93	0.92	-0.21	-0.95	0.86	0.88	1.0	-0.9

Click cells to compare fundamentals

Enfusion Account Relationship Matchups

Enfusion fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	39.1M	106.1M	123.8M	109.0M	143.3M	99.8M
Other Current Liab	5.6M	4.4M	7.4M	11.4M	19.0M	9.9M
Total Current Liabilities	10.7M	8.1M	17.4M	20.3M	27.3M	16.8M
Total Stockholder Equity	(233.6M)	55.3M	65.0M	53.7M	73.2M	76.9M
Property Plant And Equipment Net	8.8M	13.1M	22.5M	32.6M	39.0M	22.4M
Net Debt	84.6M	(64.4M)	(55.6M)	(20.2M)	(34.2M)	(32.5M)
Retained Earnings	67.8M	(328K)	(178.9M)	(172.9M)	(170.1M)	(161.6M)
Accounts Payable	484K	2.5M	1.7M	2.2M	867K	1.5M
Cash	13.9M	64.4M	62.5M	35.6M	54.5M	43.4M
Non Current Assets Total	10.2M	16.4M	27.0M	39.1M	49.7M	27.4M
Non Currrent Assets Other	1.4M	3.4M	4.5M	6.5M	10.7M	11.3M
Other Assets	1.4M	3.4M	4.5M	1.0	1.15	1.09
Cash And Short Term Investments	13.9M	64.4M	62.5M	35.6M	54.5M	43.4M
Net Receivables	12.2M	18.2M	25.9M	28.1M	32.0M	23.0M
Liabilities And Stockholders Equity	39.1M	106.1M	123.8M	109.0M	143.3M	99.8M
Non Current Liabilities Total	262.0M	538K	3.0M	11.2M	16.4M	15.6M
Other Current Assets	2.8M	13.1M	8.4M	6.2M	7.1M	7.1M
Other Stockholder Equity	(233.3M)	226.7M	244.3M	226.9M	243.9M	256.1M
Total Liab	272.7M	8.6M	20.3M	31.5M	43.7M	69.1M
Net Invested Capital	(135.0M)	55.3M	65.0M	53.7M	73.2M	76.9M
Property Plant And Equipment Gross	13.6M	21.5M	15.8M	49.3M	64.7M	67.9M
Total Current Assets	28.9M	89.7M	96.8M	69.9M	93.5M	72.4M
Accumulated Other Comprehensive Income	(212K)	(171.2M)	(504K)	(406K)	(734K)	(770.7K)
Capital Stock	(233.3M)	113K	114K	127K	129K	135.5K
Net Working Capital	18.3M	81.6M	79.4M	49.5M	66.2M	55.6M
Common Stock	(233.3M)	113K	114K	127K	129K	135.5K

When determining whether Enfusion offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enfusion's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enfusion Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enfusion Stock:

How To Invest In Enfusion

Details

Is Enfusion Stock a good investment?

Details

What is Enfusion's Net Worth?

Details

Largest Application Software Companies

View

Largest Software - Application Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enfusion. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.

To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.

You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.

Is Application Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enfusion. If investors know Enfusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enfusion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.82)

Earnings Share

0.03

Revenue Per Share

2.19

Quarterly Revenue Growth

0.139

Return On Assets

0.0305

The market value of Enfusion is measured differently than its book value, which is the value of Enfusion that is recorded on the company's balance sheet. Investors also form their own opinion of Enfusion's value that differs from its market value or its book value, called intrinsic value, which is Enfusion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enfusion's market value can be influenced by many factors that don't directly affect Enfusion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Enfusion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Enfusion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enfusion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Enfusion Cost Of Revenue vs Other Operating Expenses Analysis

Cost Of Revenue vs Other Operating Expenses

Cost Of Revenue vs Other Operating Expenses Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Other Operating Expenses

Enfusion fundamental ratios Correlations

Enfusion Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Enfusion fundamental ratios Accounts

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Tangible Assets	+ 1.0	Total Stockholder Equity
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Net Invested Capital	+ 1.0	Other Stockholder Equity
Other Stockholder Equity	+ 0.99	Total Stockholder Equity
Net Invested Capital	+ 0.99	Total Stockholder Equity

Net Invested Capital	- 0.99	Current Deferred Revenue
Other Stockholder Equity	- 0.99	Current Deferred Revenue
Inventory	- 0.98	Retained Earnings
Non Current Liabilities Total	- 0.98	Net Tangible Assets
Non Current Liabilities Total	- 0.98	Total Stockholder Equity
Current Deferred Revenue	- 0.97	Total Assets